Products

EntrolyticsMD
Motilent
Gastroenterology AI
EntrolyticsMD by Motilent is an FDA-listed, secure, cloud-based medical imaging platform optimized for gastrointestinal data, enabling clinicians to review multi-modality studies and integrate AI analysis tools for digestive diseases.
GIQuant
Motilent
Gastroenterology AI
GIQuant by Motilent is an FDA-cleared AI medical image analysis software that quantifies intestinal motility from MRI scans, primarily for assessing digestive diseases like Crohn's disease, aiding in diagnosis, monitoring, and treatment response.

See all 2 products →

About Motilent

Motilent is a leading healthcare AI company dedicated to transforming the understanding and management of digestive diseases through advanced medical image analysis. Their core mission is to enhance patient care by supporting cutting-edge research, advancing clinical trials, and ultimately changing clinical practice in gastroenterology. The company develops innovative medical imaging and collaborative technology platforms, enabling researchers and clinicians to gain deeper insights into the complexities of the gastrointestinal (GI) tract.

At the heart of Motilent’s offerings is GIQuant, a sophisticated post-processing software that quantitatively measures and tracks intestinal motility using standard magnetic resonance imaging (MRI) scans. This objective assessment of bowel movement is crucial for understanding disease progression and evaluating treatment response, particularly in conditions such as Crohn’s disease, where altered motility is often indicative of active inflammation. GIQuant holds both FDA Class II clearance and CE Mark Class IIa, making it suitable for use in both adult and pediatric populations. Complementing GIQuant, Motilent also provides EntrolyticsMD, a comprehensive imaging platform optimized for various modalities including MRI, CT, and intestinal ultrasound. This platform integrates streamlined data management with advanced processing tools, incorporating AI-powered features and GIQuant to facilitate high-quality research and clinical assessment.

Motilent’s technology is designed to deliver data-driven insights that inform therapeutic decisions, allowing physicians to more effectively monitor treatment response and potentially identify ineffective therapies sooner. This capability aims to accelerate patient treatment journeys and improve clinical outcomes. The company is committed to translating its advanced technological innovations into practical clinical applications and actively engages in groundbreaking research collaborations with international partners, with a particular emphasis on non-invasive gastroenterology technologies.

What Physicians Need to Know

Specialization in Gastrointestinal AI
Motilent is the first company to specialize in the assessment of digestive diseases using AI medical image analysis. Their primary focus areas include Inflammatory Bowel Disease (IBD), particularly Crohn's disease, as well as Irritable Bowel Syndrome (IBS) and Gastroparesis.
Quantitative Motility Assessment (GIQuant)
Their flagship product, GIQuant, is a post-processing software that works with standard cine MRI scans to measure and track intestinal movement ('motility'). It provides an objective, validated score for Crohn's disease activity, which is crucial for monitoring therapeutic response and guiding treatment decisions.
Multi-modality Imaging Platform (EntrolyticsMD)
EntrolyticsMD is Motilent's secure, cloud-based medical imaging platform optimized for gastrointestinal data. It supports the ingest, storage, viewing, quantification, and communication of various imaging modalities including MRI, CT, intestinal ultrasound (IUS), endoscopy video, and histology, streamlining workflows for clinicians and researchers.
3D Pelvic Anatomy Modeling (vEUA)
Motilent offers vEUA (Virtual Examination Under Anaesthetic), a 3D modeling technology that builds anatomically representative models of pelvic and perineal anatomy from MRI scans. This aids in visualizing complex disease, planning procedures, and enhancing communication with colleagues and patients.
Intestinal Ultrasound Data Management (Bridge)
Bridge is a secure solution for capturing, storing, and sharing intestinal ultrasound (IUS) data. It connects directly to ultrasound machines, de-identifies patient data, and integrates with Entrolytics for efficient, compliant workflows, particularly useful for large cine loops in IBD.
Regulatory Clearances & Clinical Validation
GIQuant is FDA 510K cleared (Class II) and CE marked (Class IIa) for use in adults and children. EntrolyticsMD is also listed with the FDA. Motilent emphasizes real-world evidence and their tools have been used in over 300 research projects and clinical trials globally.
Physician Tip

For physicians, Motilent's tools offer a significant advantage in managing digestive diseases. GIQuant provides objective, quantitative data on intestinal motility from MRI, enabling earlier and more informed decisions on treatment response, especially in Crohn's disease, where visual assessment can be subjective. The EntrolyticsMD platform acts as a specialized 'PACS for the gut,' centralizing multi-modality imaging data (MRI, ultrasound, endoscopy, CT) into a single, accessible, and collaborative environment. This streamlines workflow, enhances diagnostic capabilities, and supports better patient communication through advanced visualizations like vEUA. By leveraging these AI-powered insights, clinicians can move patients off ineffective therapies faster, optimize treatment pathways, and improve overall patient outcomes in complex GI conditions. The non-invasive nature of their primary assessment methods (MRI, ultrasound) also reduces patient burden compared to more invasive diagnostic tools. Consider how integrating these quantitative metrics can enhance your current monitoring protocols and multidisciplinary team discussions.

Motilent's GIQuant is integrated within a DICOM compliant workflow server and its output can be viewed in standard 'off the shelf' DICOM viewers. EntrolyticsMD supports automatic data pushes from PACS and is designed to host and integrate with both proprietary and third-party AI image analysis tools. They have also partnered with Nuance AI solutions for deployment in the U.S. healthcare market. Bridge securely connects directly to ultrasound systems for data capture. The platform is built on ISO-27001 infrastructure with HIPAA and GDPR compliance, ensuring secure and compliant data handling.

Products by Motilent

2 products in the directory

EntrolyticsMD
Motilent
Gastroenterology AI
EntrolyticsMD by Motilent is an FDA-listed, secure, cloud-based medical imaging platform optimized for gastrointestinal data, enabling clinicians to review multi-modality studies and integrate AI analysis tools for digestive diseases.
GIQuant
Motilent
Gastroenterology AI
GIQuant by Motilent is an FDA-cleared AI medical image analysis software that quantifies intestinal motility from MRI scans, primarily for assessing digestive diseases like Crohn's disease, aiding in diagnosis, monitoring, and treatment response.

What the Web Says

Motilent is a UK-based medical imaging company specializing in quantifying gut motility using MRI. Their primary product, GIQuant, is an AI-powered software designed to provide objective and non-invasive measurements of gastrointestinal function. While specific product reviews are limited on major platforms, the company is generally viewed positively within the healthcare IT and academic communities for its innovative approach to diagnosing and monitoring GI disorders.

Overall: Positive

Strengths

  • Innovative technology for gut motility assessment (GIQuant)
  • Addresses an unmet need in gastroenterology diagnostics
  • Non-invasive and objective measurement using MRI
  • Potential to improve diagnosis and treatment monitoring for GI conditions
  • Strong scientific and academic backing
  • Focus on a specialized and impactful area of medical imaging

Limitations

  • Limited public product reviews on mainstream platforms (G2, Capterra)
  • Specific employer reviews (Glassdoor) are scarce or non-existent
  • Relatively niche market, potentially slower adoption compared to broader solutions
  • Reliance on MRI infrastructure may limit accessibility in some settings
  • Newer technology, so long-term clinical impact is still being established
  • Pricing and implementation details not readily available

Based on reviews from: Motilent Official Website, Healthcare IT News articles (general mentions), Academic publications referencing Motilent's technology, Industry reports on medical imaging and AI in healthcare, Limited general web searches for reviews (G2, Glassdoor, Capterra, Reddit - no specific results found)

Last updated: 2026-07-21

Videos

News, demos, and interviews about Motilent.

Loading videos...

Videos load interactively. If none appear, search YouTube for Motilent →

View all on YouTube

Press & Coverage

Digital Health
Motilent secures additional funding for bowel care technology
Motilent received additional funding from the National Institute for Health and Care Research (NIHR) to develop and roll out technology providing data-led insights into inflammatory bowel disease and Crohn's disease. This funding will support the rollout of GiQuant to NHS hospitals.
2022-05
Tech Funding News
Motilent raises u00a31.2M to rollout its CE-marked GIQuant software
Motilent secured u00a31.2 million in NIHR funding to expand the deployment of its CE-marked GIQuant software to over 10 NHS hospitals, focusing on Inflammatory Bowel Disease and Crohn's Disease. This builds on previous investments for accelerating GIQuant's development.
2022-05
ITN Online
AI Gut-imaging Software Takes on the U.S. with FDA Clearance and National Hospital Partnership
Motilent announced FDA 510K clearance in the U.S. for its AI medical image analysis software, GIQuant, for digestive diseases. The rollout will be in partnership with Nuance AI solutions.
2021-11
DigitalHealth.London
Accelerator alumnus company Motilent receives FDA 510k clearance and national hospital partnership for gut-imaging software
Motilent's GIQuant, a product providing an objective disease activity score for small bowel Crohn's disease, received FDA 510k clearance in the USA. This technology's rollout will be in partnership with Nuance AI solutions.
2021-11
AuntMinnie
Motilent gets FDA clearance for AI gut imaging software
Motilent received U.S. FDA 510(k) clearance for GIQuant, an MR image analysis application for evaluating gastrointestinal function in digestive diseases, with an initial focus on Crohn's disease. The software will be rolled out in the U.S. in collaboration with Nuance Communications.
2021-12
Minerva Imaging
Motilent Limited and Minerva Imaging announce a strategic partnership to re-envision digestive disease research
Motilent Limited and Minerva Imaging formed a strategic partnership to transform translational research in digestive diseases. This collaboration aims to facilitate access to high-quality preclinical investigation in digestive disease models.
2023-06
Fibrotarget
UEG Week and non-invasive medical imaging: what's to come - Fibrotarget
Motilent participated in United European Gastroenterology (UEG) Week 2023, presenting scientific posters on medical imaging, fibrosis, and Crohn's disease. The company highlighted the crucial role of non-invasive imaging tools in managing inflammatory bowel disease.
2023-11
Motilent
Motilent Monthly Digest #15
Motilent announced it will provide the imaging platform for GONDOMAR, a significant fistula resource, and introduced Motilent Bridge for secure ultrasound data transfer. The company also highlighted studies on J-pouch motility and the growing interest in intestinal ultrasound.
2025-04

Frequently Asked Questions

Motilent offers GIQuant, an AI software that quantifies small bowel motility from cine MRI sequences to assess Crohn's disease activity. They also provide Entrolytics, a secure, cloud-based platform for managing and analyzing gastrointestinal imaging data, which integrates GIQuant and other tools like Bridge for ultrasound data and vEUA for 3D pelvic anatomy modeling.
Motilent's flagship product, GIQuant, is CE marked (Class IIa) and FDA Cleared (Class II, 510(k) clearance K211356) for use in adults and children. Their Entrolytics platform is HIPAA and GDPR compliant, with its infrastructure hosted on ISO-27001 certified AWS, and their quality management system is ISO 13485:2016 certified.
GIQuant is designed as a post-processing application that integrates within a DICOM compliant workflow server, allowing its output to be viewed in standard DICOM viewers. The Entrolytics platform supports various data types, including MRI DICOM and ultrasound cine loops, and can be integrated into standard reading environments like PACS or via AI marketplaces.
GIQuant provides a validated objective score for quantifying Crohn's disease activity, which can be tracked over time to support treatment decisions and clinical trials. The technology has been used in UK institutions such as Great Ormond Street Hospital and is supported by research grants from the National Institute for Health and Care Research (NIHR) for further rollout and evaluation in NHS hospitals.
Motilent offers a customer success team to assist with custom reporting and integration needs. They also partner with organizations like IBUS to deliver global online training in intestinal ultrasound, indicating a commitment to user education and support.
Motilent has a significant partnership with Nuance for the rollout of GIQuant across healthcare providers in the US. They also collaborate with numerous NHS trusts in the UK for clinical implementation and research, and have partnered with Minerva Imaging for preclinical research in digestive diseases.
Founded in 2013, Motilent specializes in AI medical image analysis for digestive diseases, with a mission to improve patient lives through advanced medical imagery and collaboration tools. They have secured funding, including grants from the NIHR, to advance and deploy their technology, focusing on supporting cutting-edge research, advancing clinical trials, and changing clinical practice in gastroenterology.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.